South African journal of gastroenterology and hepatology., Journal Year: 2024, Volume and Issue: 1(2), P. 55 - 57
Published: Sept. 1, 2024
Language: Английский
Molecular Aspects of Medicine, Journal Year: 2023, Volume and Issue: 95, P. 101231 - 101231
Published: Dec. 5, 2023
Liver fibrosis, as an excess deposition of extracellular matrix (ECM) components, results from chronic liver injury well persistent activation inflammatory response and fibrogenesis. fibrosis is a major determinant for disease (CLD) progression in the last two decades our understanding on molecular cellular mechanisms underlying fibrogenic CLD has dramatically improved, boosting pre-clinical studies clinical trials designed to find novel therapeutic approaches. From these several critical concepts have emerged, starting reveal complexity pro-fibrotic microenvironment which involves very complex, dynamic interrelated interactions between different hepatic extrahepatic cell populations. This review will offer first recapitulation established pathophysiological basic principles by intentionally focus attention NAFLD/NASH, metabolic-related form with high impact general population emerging leading cause worldwide. NAFLD/NASH-related pro-inflammatory profibrogenic be analysed information cells, mediators signalling pathways taken advantage methodological approaches techniques (single genomics, imaging mass cytometry, vitro two- three-dimensional models, etc.). We next overview recent advancement diagnostic prognostic tools, including serum biomarkers polygenic scores, support analysis biopsies. Finally, this provide current therapies treatment NAFLD/NASH patients.
Language: Английский
Citations
66
Hepatology, Journal Year: 2024, Volume and Issue: unknown
Published: Feb. 13, 2024
Liver cancer is the third leading cause of cancer-related deaths and ranks as sixth most prevalent type globally. NAFLD or metabolic dysfunction-associated steatotic liver disease, its more severe manifestation, NASH steatohepatitis (MASH), pose a significant global health concern, affecting approximately 20%-25% population. The increased prevalence disease MASH parallel to increasing rates obesity-associated diseases, including 2 diabetes, insulin resistance, fatty diseases. can progress MASH-related HCC (MASH-HCC) in about 2% cases each year, influenced by various factors such genetic mutations, carcinogen exposure, immune microenvironment, microbiome. MASH-HCC exhibits distinct molecular characteristics compared other causes affects both men women equally. management early intermediate-stage typically involves surgery locoregional therapies, while advanced treated with systemic anti-angiogenic therapies checkpoint inhibitors. In this comprehensive review, we consolidate previous research findings also providing current insights into intricate processes underlying development. We delve MASH-HCC-associated variations somatic progression models, multiomics analysis, immunological microenvironmental impacts, discuss targeted/combined overcome evasion biomarkers recognize treatment responders. By furthering our comprehension mechanisms MASH-HCC, goal catalyze advancement potent strategies, ultimately enhanced patient outcomes.
Language: Английский
Citations
41
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(8), P. 7463 - 7463
Published: April 18, 2023
Hepatocellular carcinoma is the most common primary liver cancer, ranking third among leading causes of cancer-related mortality worldwide and whose incidence varies according to geographical area ethnicity. Metabolic rewiring was recently introduced as an emerging hallmark able affect tumor progression by modulating cancer cell behavior immune responses. This review focuses on recent studies examining HCC’s metabolic traits, with particular reference alterations glucose, fatty acid amino metabolism, three major changes that have gained attention in field HCC. After delivering a panoramic picture peculiar landscape HCC, this will also discuss how reprogramming cells can affect, directly or indirectly, microenvironment function different populations, eventually favoring escape from immunosurveillance.
Language: Английский
Citations
31
Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(6), P. 1772 - 1772
Published: June 20, 2023
Chronic inflammation contributes to the pathogenesis of many diseases, including apparently unrelated conditions such as metabolic disorders, cardiovascular neurodegenerative osteoporosis, and tumors, but use conventional anti-inflammatory drugs treat these diseases is generally not very effective given their adverse effects. In addition, some alternative medications, natural compounds, have scarce solubility stability, which are associated with low bioavailability. Therefore, encapsulation within nanoparticles (NPs) may represent an strategy enhance pharmacological properties bioactive molecules, poly lactic-co-glycolic acid (PLGA) NPs been widely used because high biocompatibility biodegradability possibility finely tune erosion time, hydrophilic/hydrophobic nature, mechanical by acting on polymer's composition preparation technique. Many studies focused PLGA-NPs deliver immunosuppressive treatments for autoimmune allergic or elicit protective immune responses, in vaccination cancer immunotherapy. By contrast, this review PLGA preclinical vivo models other a key role played chronic unbalance between reparative phases inflammation, particular focus intestinal bowel disease; cardiovascular, neurodegenerative, osteoarticular, ocular diseases; wound healing.
Language: Английский
Citations
23
Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 14
Published: Jan. 19, 2024
In light of a global rise in the number patients with type 2 diabetes mellitus (T2DM) and obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated (MAFLD) or steatotic (MASLD), has become leading cause hepatocellular carcinoma (HCC), annual occurrence MASLD-driven HCC expected to increase by 45%–130% 2030. Although MASLD serious major public health threat globally, exact molecular mechanisms mediating remain an open problem, necessitating future investigation. Meanwhile, emerging studies are focusing on utility bioactive compounds halt progression HCC. this review, we first briefly review recent progress possible pathogenesis for We then discuss application mitigate through different modulatory encompassing anti-inflammatory, lipid metabolic, gut microbial pathways, providing valuable information treatment prevention Nonetheless, clinical research exploring effectiveness herbal medicines is still warranted.
Language: Английский
Citations
11
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(13), P. 10633 - 10633
Published: June 25, 2023
Chronic liver disease (CLD) is a major global health threat and has emerged as leading cause of human death [...]
Language: Английский
Citations
18
Heliyon, Journal Year: 2024, Volume and Issue: 10(15), P. e35338 - e35338
Published: July 31, 2024
Language: Английский
Citations
4
Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16
Published: April 22, 2025
Metabolic dysfunction-associated steatitic liver disease (MASLD) is the predominant chronic disease, with its incidence increasing year by year. It has emerged as most rapidly contributor to liver-related mortality worldwide and becoming a principal cause of end-stage disorders, primarily cancer transplantation, hence putting substantial economic burden on public health. The approval Resmetirom signifies significant advancement in treatment metabolic steatohepatitis (MASH); nonetheless, heterogeneity MASLD renders it challenging for single medication address requirements all patients. Consequently, essential formulate varied therapeutic approaches distinct pathogenic causes phases disease. Fibroblast growth factor 21 (FGF21), member fibroblast family, plays positive protective role MASLD. attenuates hepatic steatosis lipotoxicity, ameliorates insulin resistance (IR), reduces oxidative stress, endoplasmic reticulum (ER) inflammation, well possesses anti-fibrotic effects. As result, FGF21 potential treat In this review, we will possible mechanisms therapy facilitate development clinical therapies targeting
Language: Английский
Citations
0
Food Science & Nutrition, Journal Year: 2023, Volume and Issue: 11(12), P. 7485 - 7503
Published: Sept. 21, 2023
Abstract Non‐alcoholic fatty liver disease (NAFLD) is frequently linked to metabolic disorders and prevalent in obese diabetic patients. The pathophysiology of NAFLD involves multiple factors, including insulin resistance (IR), oxidative stress (OS), inflammation, genetic predisposition. Recently, there has been an emphasis on the use herbal remedies with many people around world resorting phytonutrients or nutraceuticals for treatment numerous health challenges various national healthcare settings. Pomegranate ( Punica granatum ) parts, such as juice, peel, seed flower, have high polyphenol content well known its antioxidant capabilities. polyphenols, hydrolyzable tannins, anthocyanins, flavonoids, capabilities that can help lower OS inflammation associated NAFLD. study aimed investigate whether pomegranate parts could attenuate OS, other risk factors NAFLD, ultimately prevent development disease. findings this revealed that: 1. juice contains hypoglycemic qualities assist manage blood sugar levels, which vital avoiding treating 2. Polyphenols from flowers increase paraoxonase 1 (PON1) mRNA protein levels liver, protect enzymes 3. Punicalagin (PU) one major ellagitannins found pomegranate, PU‐enriched extract (PE) shown inhibit HFD‐induced hyperlipidemia hepatic lipid deposition rats. 4. fruit consumption, antioxidants, decrease activity AST ALT (markers damage), TNF‐α (a marker inflammation), improve overall capacity Overall, polyphenols extracts antioxidant, anti‐inflammatory, hypoglycemic, protective effects enzymes,
Language: Английский
Citations
10
Cancers, Journal Year: 2023, Volume and Issue: 15(13), P. 3367 - 3367
Published: June 27, 2023
The aim of the systematic review is to assess prevalence and risk factors liver fibrosis in patients with Inflammatory Bowel Disease (IBD) Non-Alcoholic Fatty Liver (NAFLD) discuss role progression hepatocellular carcinoma (HCC). We performed a structured search PubMed, Web Science, Embase, Scopus up 3 March 2023 identify observational studies reporting NAFLD IBD. Quality was assessed using Newcastle-Ottawa Scale (NOS) score. A total 23 met our inclusion criteria, including 629,781 patients. 10 cross-sectional, case-control, cohort were included. Fourteen had NOS score ≥ 7 points. diagnosed 2162/6332 (34.1%) IBD participants. However, diagnosis established 924/2962 (31.2%) healthy individuals without Advanced found 116 (11.6%) 992 NAFLD. Most an association between classic cardiovascular such as older age, male sex, higher BMI, diabetes, hypertension dyslipidemia. In addition, metabolic syndrome features also associated increased significant advanced fibrosis. Although no strong therapy reported, some diagnosis, Crohn’s Disease, complicated course IBD, disease activity, duration. several studies. conclusion, are prevalent clinically relevant extraintestinal manifestations, so its potential HCC should be carefully considered daily clinical practice.
Language: Английский
Citations
8